Backes James M, Moriarty Patrick M, Ruisinger Janelle F, Gibson Cheryl A
Department of Pharmacy Practice, Kansas University Medical Center, Kansas City, Kansas, USA.
Am J Cardiol. 2007 Aug 1;100(3):554-5. doi: 10.1016/j.amjcard.2007.03.059. Epub 2007 Jun 18.
Statins possess an excellent safety profile and are generally well tolerated when administered in the standard once-daily dosing regimen. A small percentage of patients however, discontinue therapy because of adverse events such as myalgias. The investigators describe 8 patients with previous intolerance to daily statin dosing and examine their responses to once-weekly rosuvastatin therapy. In conclusion, once-weekly rosuvastatin may be a feasible and effective option for patients previously intolerant to once-daily statin dosing.
他汀类药物具有良好的安全性，以标准的每日一次给药方案服用时，通常耐受性良好。然而，一小部分患者会因肌痛等不良事件而停止治疗。研究人员描述了8例先前对每日他汀类药物给药不耐受的患者，并研究了他们对每周一次瑞舒伐他汀治疗的反应。总之，对于先前不耐受每日一次他汀类药物给药的患者，每周一次瑞舒伐他汀可能是一种可行且有效的选择。
